Chapel Hill, NC, United States of America

Xiaodong Wang

This inventor holds 37 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Cancer Therapeutics. Top assignees: The University of North Carolina at Chapel Hill, Icagen, Inc., Ecstasy LLC. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaodong Wang. Retrieved from https://idiyas.com/inventor/xiaodong-wang-tjf43y5f

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 37 (Patent Applications = 7)

% Patents Active = 70.3

CIPO Patents = 5 (Patent Applications = 7)

EPO Patents = 5 (Patent Applications = 17)

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 143(Granted Patents)

Location History:

Jiangyin, CN (2009)
Chapel Hill, NC (US) (2006 - 2024)

Company Filing History:

19 out of 1,332

The University of North Carolina at Chapel Hill

The United States of America, as Represented by the Secretary, Department of Health and Human Services

6. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

MerTK Inhibitors

Pyrrolopyrimidine Compounds

Ion Channel Modulators

Polymorphs

Sigma Receptor Modulators

Potassium Channel Modulators

Kinase Inhibitors

Thiazole Derivatives

Opioid Receptor Modulators

Pyrazolopyrimidine Compounds

Aryl Aminopyrimidines

Benzimidazoles

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12448365 - Aryl aminopyrimidines as dual MerTK and TYRO3 inhibitors and methods thereof (2025-10-21),

2. 12275737 - Polymorphs of a kinase inhibitor, pharmaceutical compositions containing such a compound, preparation methods, and applications (2025-04-14),

3. 11945810 - Amines for use as sigma receptor modulators (2024-04-02),

4. 11584765 - Polycyclic amines as sigma receptor modulators (2023-02-21),

5. 11548879 - Polycyclics as sigma receptor modulators (2023-01-10),

6. 11001586 - Alkyl pyrrolopyrimidine analogs and methods of making and using same (2021-05-11),

7. 10836759 - Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer (2020-11-17),

8. 10703746 - Mutant IDH1 inhibitors useful for treating cancer (2020-07-07),

9. 10676456 - Polycyclic amines as opioid receptor modulators (2020-06-09),

10. 10526309 - Pan-TAM inhibitors and Mer/Axl dual inhibitors (2020-01-07),

11. 10179133 - Pyrrolopyrimidine compounds for the treatment of cancer (2019-01-15),

12. 10004755 - Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity (2018-06-26),

13. 9795606 - Pyrrolopyrimidine compounds for the treatment of cancer (2017-10-24),

14. 9771330 - Pyrimidine compounds for the treatment of cancer (2017-09-26),

15. 9744172 - Pyrazolopyrimidine compounds for the treatment of cancer (2017-08-29),

Title: Xiaodong Wang: Innovator in Pharmaceutical Sciences

Introduction

Xiaodong Wang, an accomplished inventor based in Chapel Hill, North Carolina, has significantly contributed to the field of pharmaceutical sciences with a remarkable portfolio of 39 patents. His work involves the development of innovative compounds and formulations aimed at addressing various medical challenges.

Latest Patents

Among his latest patents is the invention concerning polymorphs of a kinase inhibitor, specifically the compound (trans)-4-((2-cyclopropylethyl)amino)-5-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexanol trihydrochloride. This invention details new crystal forms, preparation methods, and pharmaceutical compositions containing the compound, focusing on its application in treating various diseases and conditions.

Another notable innovation by Wang includes a patent on amines for use as sigma receptor modulators. This invention presents a variety of polycyclic amines useful as opioid receptor modulators that are applicable for therapeutic and diagnostic methods targeting conditions such as pain, neurological disorders, and even cancer.

Career Highlights

Wang's professional journey includes significant roles at reputable institutions such as the University of North Carolina at Chapel Hill and Icagen, Inc. His active engagement in research and development has positioned him as a leading figure in pharmaceutical innovation, reflecting his commitment to enhancing medical treatments through novel compounds.

Collaborations

Throughout his career, Wang has collaborated with fellow researchers, including Weihe Zhang and Stephen Frye. These partnerships have fostered a collaborative atmosphere that promotes the exploration of cutting-edge medical solutions and the advancement of pharmacological research.

Conclusion

Xiaodong Wang's extensive contributions to the pharmaceutical field exemplify the critical role innovators play in healthcare advancements. With a strong foundation in his numerous patents, he continues to push the boundaries of science and technology, seeking solutions that can improve patient outcomes and address pressing medical challenges.

Profile summary based on public USPTO records.